No. 3: Medivation (MDVN)
One day, Medivation shares are up 9% for the year. Twenty-four hours later, Medivation is up 162%. This sudden and spectacular jump in market value -- akin to winning the lottery -- is what makes biotech stocks irresistible for so many investors. Medivation's spark was the November announcement of a successful phase III study for its prostate cancer drug MDV3100.
The stock: Medivation shares weren't done moving higher after that very good, early November day. As of Dec. 16, Medivation is up 199% for the year.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV